**Impact of Advanced Glycation End Products on Endothelial Function and Their Potential Link to Atherosclerosis Endothelial Function and Their Potential Link to Atherosclerosis**

**Impact of Advanced Glycation End Products on** 

DOI: 10.5772/intechopen.73025

Ezequiel Alvarez, Beatriz Paradela-Dobarro, Mercedes González-Peteiro and José Ramón González-Juanatey Mercedes González-Peteiro and José Ramón González-Juanatey Additional information is available at the end of the chapter

Ezequiel Alvarez, Beatriz Paradela-Dobarro,

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/intechopen.73025

#### **Abstract**

[164] Colca JR et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)—Relationship to newly identified mitochondrial pyruvate carrier pro-

[165] Lois N et al. Endothelial progenitor cells in diabetic retinopathy. Frontiers in Endo-

[166] Sukmawati D, Tanaka R. Introduction to next generation of endothelial progenitor cell therapy: A promise in vascular medicine. American Journal of Translational Research.

[167] Ye L, Poh KK. Enhancing endothelial progenitor cell for clinical use. World Journal of

[168] Cappellari R et al. Plerixafor improves the endothelial health balance. The effect of diabetes analysed by polychromatic flow cytometry. Atherosclerosis. 2016;**251**:373-380 [169] Santos R et al. A comprehensive map of molecular drug targets. Nature Reviews. Drug

[170] Hopkins AL, Groom CR. The druggable genome. Nature Reviews. Drug Discovery.

teins. PLoS One. 2013;**8**(5):e61551

210 Endothelial Dysfunction - Old Concepts and New Challenges

crinology (Lausanne). 2014;**5**:44

Stem Cells. 2015;**7**(6):894-898

Discovery. 2017;**16**(1):19-34

2015;**7**(3):411-421

2002;**1**(9):727-730

The role of advanced glycation end products (AGEs) in cardiovascular diseases is a matter of interest in the last years and the strong association between the action of AGEs on their receptor (RAGE) and atherosclerosis has attracted increased attention. The aim of this chapter is to review the results of our laboratory and others on the molecular mechanisms triggered by AGEs in the endothelium that could participate in the atherosclerotic process. These mechanisms and molecular pathways could be the source of new therapeutic targets against atherosclerosis or vascular disease. Oxidative stress in endothelium induced by AGEs triggers molecular signaling pathways that produce an inflammatory response or even endothelial dysfunction. Adhesion molecules expression at the membranes of endothelial cells as a consequence of this response or induced by other mechanisms involving AGEs mediates the adhesion of leukocytes to endothelium. This adhesion is a key step in the atherogenesis process and the possible involvement of AGE-RAGE axis in this process should be considered as a potential therapeutic target. Finally, potential pharmacological modulation of AGE-RAGE axis activity at the endothelium is suggested, but the specific pharmacological tools available nowadays are missing; respectively, drugs used for the treatment of cardiovascular and metabolic diseases could be helpful for AGE-RAGE axis modulation, thus also affecting endothelial (dys)function.

**Keywords:** advanced glycation end products, atherosclerosis, endothelial dysfunction, oxidative stress, receptor for advanced glycation end products, vascular adhesion molecules, vascular inflammation

Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
